RÉSUMÉ
We demonstrate the performance characteristics of a new class of vacuum-sealed, autolocking diode laser systems and their applications to precision metrology. The laser is based on adaptations of a design that uses optical feedback from an interference filter and it includes a vacuum-sealed cavity, an interchangeable base-plate, and an autolocking digital controller. A change of the base-plate allows operation at desired wavelengths in the visible and near infrared spectral range, whereas the autolocking ability allows the laser to be tuned and frequency stabilized with respect to atomic, molecular, and solid-state resonances without human intervention using a variety of control algorithms programmed into the same controller. We characterize the frequency stability of this laser system based on the Allan deviation (ADEV) of the beat note and of the lock signal. We find that the ADEV floor of 2 × 10-12 and short-term linewidth of â¼200 kHz are strongly influenced by current noise and vacuum sealing. Reducing the current noise and cavity pressure decreases the ADEV floor and increases the averaging time at which the floor occurs, which is a signature of long-term stability. We also show that evacuating the cavity to â¼1 Torr reduces the range of the correction signal of the feedback loop by approximately one order of magnitude, thereby increasing the lock range of the controller. The long-term stability allows the laser to be incorporated into a commercial gravimeter for accurate measurements of gravitational acceleration at the level of a few parts-per-billion, which are comparable to values obtained with an iodine-stabilized He-Ne laser. The autolocking and pattern-matching features of the controller allow the laser to be tuned and stabilized with respect to a temperature tunable transmission spectrum of a fiber-Bragg grating. This capability may be suitable for the development of a differential absorption LIDAR transmitter that can generate data at both on-line and off-line lock points using a single laser.
RÉSUMÉ
Triple negative breast cancer (TNBC) is an aggressive subtype with relatively poor clinical outcomes and limited treatment options. Chemotherapy, while killing cancer cells, can result in the generation of highly chemoresistant therapeutic induced senescent (TIS) cells that potentially form stem cell niches resulting in metastases. Intriguingly, senescent cells release significantly more extracellular vesicles (EVs) than non-senescent cells. Our aim was to profile EVs harvested from TIS TNBC cells compared with control cells to identify a potential mechanism by which TIS TNBC cells maintain survival in the face of chemotherapy. TIS was induced and confirmed in Cal51 TNBC cells using the chemotherapeutic paclitaxel (PTX) (Taxol). Mass spectrometry (MS) analysis of EVs harvested from TIS compared with control Cal51 cells was performed using Ingenuity Pathway Analysis and InnateDB programs. We demonstrate that TIS Cal51 cells treated with 75 nM PTX for 7 days became senescent (senescence-associated ß-galactosidase (SA-ß-Gal) positive, Ki67-negative, increased p21 and p16, G2/M cell cycle arrest) and released significantly more EVs (P=0.0002) and exosomes (P=0.0007) than non-senescent control cells. Moreover, TIS cells displayed an increased expression of the multidrug resistance protein 1/p-glycoprotein. MS analysis demonstrated that EVs derived from senescent Cal51 cells contained 142 proteins with a significant increased fold change compared with control EVs. Key proteins included ATPases, annexins, tubulins, integrins, Rabs and insoluble senescence-associated secretory phenotype (SASP) factors. A fluorescent analogue of PTX (Flutax-2) allowed appreciation of the removal of chemotherapy in EVs from senescent cells. Treatment of TIS cells with the exosome biogenesis inhibitor GW4869 resulted in reduced SA-ß-Gal staining (P=0.04). In summary, this study demonstrates that TIS cells release significantly more EVs compared with control cells, containing chemotherapy and key proteins involved in cell proliferation, ATP depletion, apoptosis and the SASP. These findings may partially explain why cancer senescent cells remain viable despite chemotherapeutic challenge.
RÉSUMÉ
The goal of this project was to determine the pharmacokinetics of voriconazole and its concentration in cerebrospinal fluid (CSF), aqueous humor, and synovial fluid in five healthy dogs following once daily oral dose of 6 mg/kg for 2 weeks. Body fluid and plasma drug concentrations were determined by high-performance liquid chromatography (HPLC). Mild to moderate gastrointestinal adverse effects were seen. The mean AUC0-24 : minimum inhibitory concentration (MIC) ratio was 15.23 for a chosen MIC of 1 µg/mL, which is lower than the recommended target of 20-25 and also lower than previously reported in dogs, perhaps reflecting induction of metabolizing enzymes by multiple dosing. Voriconazole concentrations in the CSF, aqueous humor, and synovial fluid were only 13-30% the concurrent plasma concentration, which is lower than previously reported in other species. Results of this study suggest that twice daily, administration may be necessary to maintain therapeutic plasma concentrations in dogs but further studies are warranted.
Sujet(s)
Antifongiques/pharmacocinétique , Voriconazole/pharmacocinétique , Administration par voie orale , Animaux , Antifongiques/administration et posologie , Antifongiques/analyse , Antifongiques/sang , Antifongiques/liquide cérébrospinal , Humeur aqueuse/composition chimique , Chromatographie en phase liquide à haute performance/médecine vétérinaire , Chiens , Femelle , Mâle , Tests de sensibilité microbienne/médecine vétérinaire , Synovie/composition chimique , Voriconazole/administration et posologie , Voriconazole/analyse , Voriconazole/sang , Voriconazole/liquide cérébrospinalRÉSUMÉ
Antimicrobial efficacy against Lawsonia intracellularis is difficult to evaluate in vitro, thus, the effects of gallium maltolate's (GaM) were investigated in a rabbit model for equine proliferative enteropathy (EPE). Juvenile (5-6-week-old) does were infected with 3.0 × 10(8) L. intracellularis/rabbit and allocated into three groups (n = 8). One week postinfection, one group was treated with GaM, 50 mg/kg; one, with doxycycline, 5 mg/kg; and one with a sham-treatment (control). Feces and blood were collected daily and weekly, respectively, to verify presence of L. intracellularis fecal shedding using qPCR, and seroconversion using immunoperoxidase monolayer assay. Rabbits were sacrificed after 1 week of treatment to collect intestinal tissues focusing on EPE-affected sections. Intestinal lesions were confirmed via immunohistochemistry. No difference was noted between treatments regarding EPE-lesions in jejunum (P = 0.51), ileum (P = 0.74), and cecum (P = 0.35), or in L. intracellularis fecal shedding (P = 0.64). GaM and doxycycline appear to have similar efficacy against EPE in infected rabbits.
Sujet(s)
Antibactériens/usage thérapeutique , Infections à Desulfovibrionaceae/médecine vétérinaire , Lawsonia (bactérie)/effets des médicaments et des substances chimiques , Composés organométalliques/usage thérapeutique , Pyrones/usage thérapeutique , Animaux , Infections à Desulfovibrionaceae/traitement médicamenteux , Infections à Desulfovibrionaceae/microbiologie , Infections à Desulfovibrionaceae/anatomopathologie , Modèles animaux de maladie humaine , Femelle , Lapins , Résultat thérapeutiqueRÉSUMÉ
Oral gallium maltolate (GaM) pharmacokinetics (PK) and intestinal tissue (IT) concentrations of elemental gallium ([Ga]) and iron ([Fe]) were investigated in a rabbit model of equine proliferative enteropathy (EPE). New Zealand white does (uninfected controls and EPE-infected, n = 6/group) were given a single oral GaM dose (50 mg/kg). Serial blood samples were collected from 0 to 216 h post-treatment (PT) and IT samples after euthanasia. Serology, qPCR, and immunohistochemistry confirmed, or excluded, EPE. Blood and IT [Ga] and [Fe] were determined using inductively coupled plasma-mass spectrometry. PK parameters were estimated through noncompartmental approaches. For all statistical comparisons on [Ga] and [Fe] α = 5%. The Ga log-linear terminal phase rate constant was lower in EPE rabbits vs. uninfected controls [0.0116 ± 0.004 (SD) vs. 0.0171 ± 0.0028 per hour; P = 0.03]; but half-life (59.4 ± 24.0 vs. 39.4 ± 10.8 h; P = 0.12); Cmax (0.50 ± 0.21 vs. 0.59 ± 0.42 µg/mL; P = 0.45); tmax (1.75 ± 0.41 vs. 0.9 ± 0.37 h; P = 0.20); and oral clearance (6.743 ± 1.887 vs. 7.208 ± 2.565 L/h; P = 0.74) were not. IT's [Ga] and [Fe] were higher (P < 0.0001) in controls. In conclusion, although infection reduces IT [Ga] and [Fe], a 48 h GaM dosing interval is appropriate for multidose studies in EPE rabbits.
Sujet(s)
Antibactériens/pharmacocinétique , Antibactériens/usage thérapeutique , Infections à Desulfovibrionaceae/microbiologie , Lawsonia (bactérie) , Composés organométalliques/pharmacocinétique , Composés organométalliques/usage thérapeutique , Pyrones/pharmacocinétique , Pyrones/usage thérapeutique , Animaux , Infections à Desulfovibrionaceae/traitement médicamenteux , Femelle , Période , LapinsRÉSUMÉ
A generally applicable, easy-to-use method of focusing a patient's immune system to eradicate or prevent cancer has been elusive. We are attempting to develop a targeted virus to accomplish these aims. We previously created a recombinant replicating vesicular stomatitis virus (VSV) that preferentially infected Her2/neu expressing breast cancer cells and showed therapeutic efficacy in an implanted Balb/c mouse tumor model. The current work shows that this therapy generated therapeutic anti-tumor CD4 T cells against multiple tumor antigens. CD4 T cells transferred directly from cured donor mice could eradicate established tumors in host mice. T cells were transferred directly from donor mice and were not stimulated ex vivo. Both tumors that expressed Her2/neu and those that did not were cured by transferred T cells. Analysis of cytokines secreted by anti-tumor memory CD4 T cells displayed a multifunctional pattern with high levels of interferon-γ, interleukin (IL)-4 and IL-17. Anti-tumor memory CD4 T cells traveled to the mesenteric lymph nodes and were activated there. Treatment with targeted recombinant replicating VSV is a potent immune adjuvant that generates therapeutic, multifunctional anti-tumor memory CD4 T cells that recognize multiple tumor antigens. Immunity elicited by viral therapy is independent of host major histocompatibility complex or knowledge of tumor antigens. Virus-induced tumor immunity could have great benefit in the prevention and treatment of tumor metastases.
Sujet(s)
Lymphocytes T CD4+/immunologie , Vecteurs génétiques/génétique , Mémoire immunologique/immunologie , Tumeurs/génétique , Tumeurs/immunologie , Virus de la stomatite vésiculeuse de type Indiana/génétique , Transfert adoptif , Animaux , Lymphocytes B/immunologie , Lymphocytes T CD8+/immunologie , Lignée cellulaire , Cytokines/biosynthèse , Femelle , Vecteurs génétiques/administration et posologie , Vecteurs génétiques/immunologie , Humains , Souris , Souris de lignée BALB C , Tumeurs/mortalité , Tumeurs/thérapie , Virus de la stomatite vésiculeuse de type Indiana/immunologieRÉSUMÉ
Iron deficiency is a widespread form of malnutrition and is known to interfere with cognitive performance and development. To elucidate the role of dopamine D3 and iron deficiency (ID) in inducing cognitive deficits, we studied wildtype and D3 knockout mice on normal or iron-deficient diets subjected to a running wheel-based motor skill sequence. Surprisingly, ID alone had no effect on motor learning in this study, whereas combined ID and dopamine D(3) receptor (D3R)-deficiency significantly interfered with the acquisition of motor skills. Reduced D3R function may serve as a predisposing factor towards ID-related effects on motor learning.
Sujet(s)
Carences en fer , Incapacités d'apprentissage , Aptitudes motrices/physiologie , Récepteur D3 de la dopamine/déficit , Facteurs âges , Analyse de variance , Animaux , Comportement animal , Régime alimentaire/méthodes , Incapacités d'apprentissage/génétique , Incapacités d'apprentissage/métabolisme , Incapacités d'apprentissage/physiopathologie , Souris , Souris de lignée C57BL , Souris knockout , Course à pied/physiologie , Facteurs tempsRÉSUMÉ
This study reports on the use of an atmospheric plasma technique to incorporate metal oxide nanoparticles into nm thick siloxane coatings. Titanium dioxide (TiO2) particles with diameters of 30-80 nm, were mixed with a number of different siloxanes-polydimethylsiloxane, hexamethyldisiloxane and tetraethylorthosilicate (TEOS). The TiO2/TEOS mixture was found to give the most stable suspension, possibly due to the higher surface tension of TEOS compared with the other siloxanes. TiO2/TEOS mixtures with 2 to 10% by weight of the metal oxide were prepared and were then nebulised into a helium/oxygen atmospheric plasma. Polyethylene terepthalate (PET) and silicon wafer substrates were passed through this plasma using a reel-to-reel substrate manipulation system. SEM combined with EDX was used to examine the distribution of the metal oxide particles in the resultant coatings. The TEOS coating thickness without TiO2 addition was 9 nm. The composite coating consisted of a relatively homogeneous distribution of small agglomerates of the TiO2 nanoparticles in TEOS. A linear increase in the titanium surface concentration was observed with increase in the quantity of TiO2 added into the siloxane precursor. The chemical functionality of the siloxane coating was examined using FTIR spectroscopy and no significant spectrum differences was observed with the incorporation of the different concentrations of TiO2 into the polymer. There were also no changes observed in coating surface energy with TiO2 incorporation. Coating morphology was examined using optical profilometry and surface roughness (Ra) values increased from typical values of 0.8 nm for the TEOS coating to 4.1 nm for the TiO2/TEOS coating. The adhesion of the deposited coatings was compared using fragmentation tests. These were carried out through uniaxial tensile loading. The coating cracking pattern after applied strain of 20% was not observed to change significantly with the addition of TiO2 into the siloxane.
RÉSUMÉ
In this study we have identified a functional role for miR-29a in cancer cell invasion and proliferation. MiRNA expression profiling of human NSCLC cell lines indicated that miR-29a levels were reduced in more invasive cell lines. Exogenous overexpression of miR-29a in both lung and pancreatic cancer cell lines resulted in a significant reduction in the invasion phenotype, as well as in proliferation. 2D DIGE proteomic profiling of cells transfected with pre-miR-29a or anti-miR-29a resulted in the identification of over 100 differentially regulated proteins. The fold change of protein expression was generally modest--in the range 1.2-1.7-fold. Only 14 were predicted computationally to have miR-29a seed sequences in their 3' UTR region. Subsequent studies using siRNA to knock down several candidate proteins from the 2D DIGE experiment identified RAN (a member of the RAS oncogene family) which significantly reduced the invasive capability of a model lung cancer cell line. We conclude that miR-29a has a significant anti-invasive and anti-proliferative effect on lung cancer cells in vitro and functions as an anti-oncomir. This function is likely mediated through the post-transcriptional fine tuning of the cellular levels of several proteins, both directly and indirectly, and in particular we provide some evidence that RAN represents one of these.
Sujet(s)
Carcinome pulmonaire non à petites cellules/métabolisme , Régulation de l'expression des gènes tumoraux/génétique , Tumeurs du poumon/métabolisme , microARN/génétique , Protéines tumorales/biosynthèse , Carcinome pulmonaire non à petites cellules/génétique , Carcinome pulmonaire non à petites cellules/anatomopathologie , Lignée cellulaire tumorale , Prolifération cellulaire , Régulation négative/génétique , Analyse de profil d'expression de gènes/méthodes , Techniques de knock-down de gènes , Humains , Tumeurs du poumon/génétique , Tumeurs du poumon/anatomopathologie , Invasion tumorale/génétique , Protéines tumorales/génétique , Phénotype , Protéomique/méthodes , ARN messager/analyse , Petit ARN interférent/génétique , RT-PCR/méthodes , Transfection , Protéine G ran/génétiqueRÉSUMÉ
This paper describes the pharmacokinetic profile of procaine penicillin G after intraperitoneal (IP) administration in eight lactating dairy cows. Procaine pencillin G (PPG, 21 000 IU/kg) was deposited into the abdominal cavity of each cow following an incision in the right paralumbar fossa. Blood and milk samples were taken over the following 10 days, at which point the cows were euthanized. Plasma, milk, muscle, liver, and kidney penicillin concentrations were determined by HPLC, with a limit of quantification of 5 ng/mL for plasma and milk and 40 ng/g for tissue samples. A noncompartmental method was used to analyze plasma kinetics. The mean pharmacokinetic parameters (+/-SD) were: C(max), 5.5 +/- 2.6 microg/mL; T(max), 0.75 +/- 0.27 h; AUC(0-infinity), 10.8 +/- 4.9 microg x h/mL; MRT, 2.2 +/- 0.9 h. All milk from treated cows contained detectable penicillin residues for a minimum of three milkings (31 h) and maximum of five milkings (52 h) after administration. Concentrations of penicillin in all muscle, liver, and kidney samples taken 10 days postadministration were below the limit of quantification. Necropsy examinations revealed foci of hemorrhage on the rumenal omentum of most cows but peritonitis was not observed. Systemic inflammation as determined by change in leukogram or plasma fibrinogen was noted in one cow. The results of this study demonstrate that IP PPG is absorbed and eliminated rapidly in lactating dairy cows.
Sujet(s)
Antibactériens/pharmacocinétique , Bovins/métabolisme , Résidus de médicaments/pharmacocinétique , Lait/métabolisme , Benzylpénicilline procaïne/pharmacocinétique , Animaux , Antibactériens/sang , Chromatographie en phase liquide à haute performance/médecine vétérinaire , Euthanasie animale , Femelle , Injections péritoneales/médecine vétérinaire , Rein/métabolisme , Lactation , Foie/métabolisme , Muscles squelettiques/métabolisme , Benzylpénicilline procaïne/sangSujet(s)
Antibactériens/pharmacocinétique , Céfalexine/pharmacocinétique , Chiens/métabolisme , Administration par voie orale , Animaux , Antibactériens/sang , Biodisponibilité , Céfalexine/sang , Chromatographie en phase liquide/médecine vétérinaire , Études croisées , Chiens/sang , Femelle , Modèles linéaires , MâleRÉSUMÉ
Vesicular stomatitis virus (VSV) is being developed for cancer therapy. We created a recombinant replicating VSV (rrVSV) that preferentially infected Her2/neu expressing breast cancer cells. We now used this rrVSV to treat macroscopic peritoneal tumor implants of a mouse mammary tumor cell line stably transfected to express Her2/neu. rrVSV therapy alone prolonged survival but did not cure any animals. rrVSV therapy combined with antibody to TGFb or antibody to IL-10 receptor (IL-10R) each produced cure in one of six animals. Strikingly, rrVSV therapy combined with anti-CTLA4 monoclonal antibody (MAb) produced cure in four of five animals. Anti-CTLA4 MAb was only effective when administered within one day of rrVSV therapy. Cure required CD4 T-cells early (<7 days) and late (>7 days) after rrVSV therapy whereas CD8 T-cells were required only late (>7 days) after rrVSV therapy. Surviving animals were resistant to re-challenge with D2F2/E2 suggesting a memory immune response. Histopathologic analysis demonstrated a dense inflammatory infiltrate of tumor nodules within days of therapy and foamy histiocytes replacing the tumor nodules 2 weeks following therapy. These studies demonstrate that targeted rrVSV combined with anti-CTLA4 MAb can eliminate established macroscopic tumor implants by eliciting an anti-tumor CD4 and CD8 T-cell immunologic response.
Sujet(s)
Anticorps monoclonaux/pharmacologie , Antigènes CD/immunologie , Mémoire immunologique , Tumeurs expérimentales de la mamelle/thérapie , Récepteur ErbB-2/immunologie , Vesiculovirus , Animaux , Anticorps monoclonaux/immunologie , Lymphocytes T CD4+/immunologie , Lymphocytes T CD4+/métabolisme , Lymphocytes T CD4+/anatomopathologie , Lymphocytes T CD8+/immunologie , Lymphocytes T CD8+/métabolisme , Lymphocytes T CD8+/anatomopathologie , Antigène CTLA-4 , Lignée cellulaire tumorale , Femelle , Régulation de l'expression des gènes tumoraux/génétique , Régulation de l'expression des gènes tumoraux/immunologie , Humains , Mémoire immunologique/effets des médicaments et des substances chimiques , Inflammation/génétique , Inflammation/immunologie , Inflammation/métabolisme , Inflammation/anatomopathologie , Tumeurs expérimentales de la mamelle/génétique , Tumeurs expérimentales de la mamelle/immunologie , Tumeurs expérimentales de la mamelle/métabolisme , Tumeurs expérimentales de la mamelle/anatomopathologie , Souris , Souris de lignée BALB C , Récepteur ErbB-2/biosynthèse , Facteurs temps , TransfectionRÉSUMÉ
The macrolide antibiotic tilmicosin has potential for treating bacterial respiratory tract infections in horses. A pharmacokinetic study evaluated the disposition of tilmicosin in the horse after oral (4 mg/kg) or subcutaneous (s.c.) (10 mg/kg) administration. Tilmicosin was not detected in equine plasma or tissues after oral administration at this dose. With s.c. injection, tilmicosin concentrations reached a maximum concentration of approximately 200 ng/mL in the plasma of the horses. Tilmicosin concentrations in plasma persisted with a mean residence time (MRT) of 19 h. Maximum tissue residue concentrations (C(max)) of tilmicosin measured in equine lung, kidney, liver and muscle tissues after s.c. administration were 2784, 4877, 1398, and 881 ng/g, respectively. The MRT of tilmicosin in these tissues was approximately 27 h. Subcutaneous administration of tilmicosin resulted in severe reactions at the injection sites.
Sujet(s)
Antibactériens/pharmacologie , Equus caballus/métabolisme , Macrolides/pharmacologie , Tylosine/analogues et dérivés , Administration par voie orale , Animaux , Antibactériens/administration et posologie , Antibactériens/sang , Antibactériens/métabolisme , Aire sous la courbe , Femelle , Injections sous-cutanées/médecine vétérinaire , Rein/métabolisme , Foie/métabolisme , Poumon/métabolisme , Macrolides/administration et posologie , Macrolides/sang , Macrolides/métabolisme , Muscles squelettiques/métabolisme , Tylosine/administration et posologie , Tylosine/sang , Tylosine/métabolisme , Tylosine/pharmacologieRÉSUMÉ
BACKGROUND: Selection of the human drug sensitive and invasive cell line (MDA-MB-435S-F) with the chemotherapeutic agent paclitaxel, resulted in the development of drug resistant cell lines displaying enhanced invasion-related characteristics. MATERIALS AND METHODS: Serum-free conditioned media from the human cancer drug-sensitive and invasive cell line (MDA-MB-435S-F) and its paclitaxel-resistant superinvasive variant (MDA-MB-435S-F/Taxol10p4pSI) were analyzed using Surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS). RESULTS: A differentially expressed protein was observed at 7.6 kDa, which was 4-fold up-regulated in MDA-MB-435S-F/Taxol10p4pSI. The differentially expressed protein was identified using matrix-assisted laser desorption ionization tandem time-of-flight mass spectrometry (MALDI-TOF/TOF MS), as a fragment of bovine transferrin. The transferrin receptor was also found to be overexpressed in the superinvasive cell line. CONCLUSION: Cleavage of serum proteins such as transferrin could provide a valuable source of markers for malignant tumours and could also play a role in aspects of cancer pathogenesis, such as tumour cachexia.
Sujet(s)
Marqueurs biologiques tumoraux/isolement et purification , Tumeurs du sein/composition chimique , Protéines tumorales/isolement et purification , Fragments peptidiques/isolement et purification , Transferrine/isolement et purification , Adulte , Marqueurs biologiques tumoraux/composition chimique , Tumeurs du sein/traitement médicamenteux , Tumeurs du sein/métabolisme , Tumeurs du sein/anatomopathologie , Lignée cellulaire tumorale , Milieux de culture conditionnés , Résistance aux médicaments antinéoplasiques , Femelle , Humains , Invasion tumorale , Protéines tumorales/composition chimique , Paclitaxel/pharmacologie , Fragments peptidiques/composition chimique , Récepteurs à la transferrine/biosynthèse , Récepteurs à la transferrine/composition chimique , Récepteurs à la transferrine/isolement et purification , Spectrométrie de masse MALDI/méthodes , Transferrine/composition chimiqueSujet(s)
Amoxicilline/pharmacocinétique , Antibactériens/pharmacocinétique , Chats/métabolisme , Administration par voie orale , Amoxicilline/administration et posologie , Amoxicilline/sang , Animaux , Antibactériens/administration et posologie , Antibactériens/sang , Aire sous la courbe , Chimie pharmaceutique , MâleRÉSUMÉ
Age-related changes in the number and size of large cholinergic terminals immunoreactive for vesicular acetylcholine transporter (VAChT), were documented for the dorsolateral nucleus (DLN), retrodorsolateral nucleus (RDLN) and spinal nucleus of the bulbospongiosus (SNB) of the lumbosacral spinal cord of male rats. The most significant changes were a large increase in the number and size of cholinergic terminals within the DLN of aged animals, together with a small decrease in terminal number within the RDLN. No significant age-associated differences in VAChT labeling were seen within the SNB. In both age groups, SNB motoneurons projecting to the levator ani muscle received about 9 to 10 contacts from large cholinergic terminals. Ultrastructural examination of the terminals revealed structures likely to be postsynaptic subsurface cisterns that are characteristic of type C terminal boutons. Since both the DLN and SNB contain motoneurons innervating pelvic muscles and sphincters, these findings provide further evidence for a central cholinergic influence on micturition and sexual reflexes and suggest that this may remain robust in the face of ageing.
Sujet(s)
Vieillissement , Voies efférentes/métabolisme , Motoneurones/métabolisme , Pelvis/innervation , Moelle spinale/physiologie , Transporteurs vésiculaires de l'acétylcholine/métabolisme , Analyse de variance , Animaux , Toxine cholérique/métabolisme , Voies efférentes/ultrastructure , Immunohistochimie , Région lombosacrale , Mâle , Microscopie immunoélectronique/méthodes , Motoneurones/ultrastructure , Rats , Rat WistarRÉSUMÉ
PURPOSE OF THE STUDY: To assess satisfaction with undergraduate orthodontic training, the variety of treatments undertaken in general practice, practitioners' perceived competence in orthodontics and the level of interest in continuing education in orthodontics. DESIGN: Cross-sectional questionnaire-based study. MATERIALS AND METHODS: A questionnaire was mailed to 520 general practitioners in Dublin, Kildare and Wicklow as listed in Irish Dental Council Register of Dentists 2003. RESULTS: Forty-six percent of dentists responded. More than half (54 per cent) of the respondents were satisfied with both academic and clinical aspects of undergraduate training. Twenty-nine percent regularly perform orthodontic treatment. Only 60 percent feel comfortable treating orthodontic emergencies. Over 70 percent have either already attended or aspire to attend further training in orthodontic diagnosis and interceptive orthodontics. CONCLUSIONS: Our study indicates that in the greater Dublin area, graduates (those qualified less than 10 years) are increasingly satisfied with undergraduate teaching. Orthodontic treatment is performed regularly in general dental practice with interceptive procedures most often carried out. While ability to deal with orthodontic emergencies is not universal, practitioners do appear confident to perform a variety of orthodontic procedures. Interest in continuing education in orthodontics is very high. Our study indicates that participation in continuing education in orthodontics appears to translate into greater provision of orthodontic care in general practice.